Jaguar Health Secures Licensing Agreement with Future Pak

Jaguar Health Inc. has signed a U.S. licensing agreement with Future Pak for Mytesi and Canalevia-CA1. This deal brings in $18 million in upfront non-dilutive cash and potential additional milestone payments of up to $20 million. The transaction simplifies Jaguar’s operations by transferring U.S. commercial execution and operating costs for Mytesi to a partner, reducing risk and improving liquidity visibility.

Jaguar's strategic refocus on crofelemer for rare intestinal failure indications is supported by encouraging clinical data, showing a significant reduction in life-sustaining parenteral support. Regulatory processes are advancing with the FDA and EMA, with efforts for a Breakthrough Therapy Designation underway. Analyst Christian Orquera from First Berlin Equity Research maintains a BUY rating, albeit revising the target price to $7.50.